Overview of ASH 2025 Trends in ADC R&D
What’s Inside the Report?
Get a clear, concise look at the most important ADC developments from ASH 2025, all in one easy-to-navigate report:
- Abstract coverage: Analysis of 87 clinical ADC abstracts and 5 preclinical ADC-focused studies, organized by disease and therapeutic focus.
- Emerging trends: Growth in ASGPR-targeted therapies, including VSA012’s first phase 1 trials, alongside Fitusiran, Cemdisiran, and Sapablursen.
- Indication highlights: Lymphoma (33 abstracts), leukemia (29), and myeloma (24), including early clinical insights on SGN-35C and HDM2005.
- Key insights: Analyst-curated trends in targets, modalities, and early-stage innovations to guide strategy, competitive intelligence, and clinical planning.
Stay on top of ASH 2025 without the time-consuming review of every abstract, this report distills the data into the insights that matter most.
You May Also Be Interested In…
Learn More About ADC
What is Beacon ADC?
- The Most Comprehensive Way to Search the ADC Drug Development Landscape: Unique search ontologies based on ADC drug and trial characteristics
- Market Leading Approach to ADC Preclinical & Clinical Data Curation: Manual curation of key ADC research and development data points by ADC research scientists
- Seamlessly Integrate Commercial & Scientific Data all in One Place: Search ADC company and deal data based on their pipeline and technologies.
- Unrivalled Granularity in Reports & Analysis: Our search ontology and technology indexing enable comprehensive analysis not seen elsewhere.
What is Beacon?
Beacon is a world leading data analysis tool for preclinical and clinical trial information. With unrivalled granularity of search function, data quality, and exhaustiveness, Beacon provides timely information and gives you confidence to progress your targeted drug therapies to patients.
Learn more about how our clinical trials and drug database solutions can be tailored to your research requirements
